Development of oncolytic viruses for cancer therapy

Abd‐Aziz, Noraini; Poh, Chit Laa

doi:10.1016/j.trsl.2021.04.008

Cited by 41 publications

(31 citation statements)

References 179 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Like other anticancer therapies, oncolytic virotherapy has several limitations, such as viral delivery to the target, penetration into the tumor mass, and antiviral immune responses. 30 The potential of oncolytic virotherapy combined with other treatments could form part of future multimodality treatment strategies.…”

Section: Discussionmentioning

confidence: 99%

Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma

Zhang

Lin

Wang

et al. 2022

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

Although chimeric antigen receptor T cell (CAR-T) therapy has been successful for hematological malignancies, it is less effective for solid tumors. The primary reason is that the immune microenvironment restricts CAR-T cells from infiltrating and proliferating in tumors. Oncolytic virotherapy has emerged as a novel immunogenic therapy to augment antitumor immune response. Here we combined an oncolytic adenovirus carrying decorin with a CAR-T targeting carbonic anhydrase IX (CAIX) to perform the antitumor activity for renal cancer cells. We found that OAV-Decorin combined with CAIX-CAR-T exhibited significantly reduced tumor burden, altered the composition of extracellular matrix (ECM) by inhibiting the distribution of collagen fibers, decreased the expression of TGF-β in tumor cells, enhanced IFN-γ secretion, and obtained higher numbers of CAR-T cells. The combination treatment modality showed prolonged mice survival. The intratumoral injection of OAV-Decorin into tumor-bearing immunocompetent mice activated the inflammatory immune status and resulted in tumor regression. These data supported further investigation of the combination of OAV-Decorin and CAIX-CAR-T cells in solid tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma

Zhang

Lin

Wang

et al. 2022

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

show abstract

“…Therefore, the safety and effectiveness of this type of genetically engineered OVs are improved. Virtually all kinds of viruses, including HSV, adenovirus, vaccinia virus, measles virus, parvovirus, poliovirus, Malaba virus, reovirus, coxsackie virus, vesicular stomatitis virus, Newcastle disease virus, and picornavirus, can be engineered to recombinant OVs [10] .…”

Section: Viral Types Of Ovsmentioning

confidence: 99%

“…In addition, it is very important to design reasonable treatment strategies according to the characteristics of different tumors and different viruses to improve efficacy. OVs alone can produce a certain curative effect, OVs combined with other cancer therapies can produce synergistic efficacy and show a strong therapeutic potential [ 10 , 77 , 78 ].…”

Section: Therapeutic Strategy Of Ovsmentioning

confidence: 99%

Current landscape and perspective of oncolytic viruses and their combination therapies

Qin

2022

Translational Oncology

View full text Add to dashboard Cite

“…Oncolytic viruses can be divided into two broad categories, those that occur naturally and those that have been genetically modified by humans. Naturally occurring OVs include eutherovirus (Reo), Newcastle disease virus (NDV), enterovirus and measles virus (MV), and microvirus H-1 (H-1PV or Parvoryx), which are used in their native form.On the other hand, human modified viruses, such as herpes simplex virus (HSV), adenovirus (Ad), and cowpox virus (VV), are genetically modified viruses ( 64 ).…”

Section: Use Of Oncolytic Virusesmentioning

confidence: 99%

“…Reo ( 73 ) is a member of the family Reooviridae and is an envelope-free double-stranded RNA virus ( 64 ). Induction of interferon (IFN) secretion and innate immune activation in human primary liver tissue in the absence of cytotoxicity and independent of viral genome replication.…”

Section: Use Of Oncolytic Virusesmentioning

confidence: 99%

Feasibility of hepatocellular carcinoma treatment based on the tumor microenvironment

et al. 2022

View full text Add to dashboard Cite

The incidence of liver cancer is extremely high worldwide and poses a serious threat to human life and health. But at present, apart from radiotherapy, chemotherapy, liver transplantation, and early resection, sorafenib was the main systemic therapy proven to have clinical efficacy for unresectable liver cancer (HCC) until 2017. Despite the emerging immunotherapy in the past decade with immune inhibitors such as PD - 1 being approved and applied to clinical treatment, there are still some patients with no response. This review aims to elucidate the mechanisms underlying the tumor microenvironment of hepatocellular carcinoma and thus analyze the effectiveness of targeting the tumor microenvironment to improve the therapeutic efficacy of hepatocellular carcinoma, including the effectiveness and feasibility of immunotherapy, tumor oncolytic viruses and anti-vascular proliferation therapy.

show abstract

Development of oncolytic viruses for cancer therapy

Cited by 41 publications

References 179 publications

Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma

Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma

Current landscape and perspective of oncolytic viruses and their combination therapies

Feasibility of hepatocellular carcinoma treatment based on the tumor microenvironment

Contact Info

Product

Resources

About